NEU 2.81% $18.65 neuren pharmaceuticals limited

from a business point of view, I would have thought failure of a...

  1. 2,647 Posts.
    lightbulb Created with Sketch. 432
    from a business point of view, I would have thought failure of a potential competitor was a good thing.

    The share price did a similar slow decay before the Rett results came out last year, with the occasional blip upwards along the way.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.